183 related articles for article (PubMed ID: 22129984)
1. Crizotinib.
Shaw AT; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2011 Dec; 10(12):897-8. PubMed ID: 22129984
[No Abstract] [Full Text] [Related]
2. Crizotinib (xalkori) for non-small cell lung cancer.
Med Lett Drugs Ther; 2012 Feb; 54(1383):11-2. PubMed ID: 22354221
[No Abstract] [Full Text] [Related]
3. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib: an anaplastic lymphoma kinase inhibitor.
Gadgeel SM; Bepler G
Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
Ou SH
Expert Rev Anticancer Ther; 2012 Feb; 12(2):151-62. PubMed ID: 22316363
[TBL] [Abstract][Full Text] [Related]
6. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
Giroux Leprieur E; Wislez M
Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
[No Abstract] [Full Text] [Related]
7. Trial watch: success for crizotinib in ALK-driven cancer.
Nat Rev Drug Discov; 2010 Dec; 9(12):908. PubMed ID: 21119722
[No Abstract] [Full Text] [Related]
8. Crizotinib: in locally advanced or metastatic non-small cell lung cancer.
Curran MP
Drugs; 2012 Jan; 72(1):99-107. PubMed ID: 22191798
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
Guo L; Zhang H; Shao W; Chen B
Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
[TBL] [Abstract][Full Text] [Related]
12. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
Gilbert JA
Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
[No Abstract] [Full Text] [Related]
13. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Arnaoutakis K
N Engl J Med; 2015 Feb; 372(7):683. PubMed ID: 25671265
[No Abstract] [Full Text] [Related]
15. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Shaw AT; Solomon BJ
N Engl J Med; 2015 Feb; 372(7):683-4. PubMed ID: 25671264
[No Abstract] [Full Text] [Related]
16. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.
Toyokawa G; Hirai F; Inamasu E; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y
J Thorac Oncol; 2014 Dec; 9(12):e86-7. PubMed ID: 25393798
[No Abstract] [Full Text] [Related]
17. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
18. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL
J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230
[No Abstract] [Full Text] [Related]
19. Crizotinib in ALK-positive lung cancer.
Girard N
Lancet Oncol; 2012 Oct; 13(10):962-3. PubMed ID: 22954506
[No Abstract] [Full Text] [Related]
20. Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC.
Zhang YC; Zhou Q; Wu YL
Expert Opin Pharmacother; 2016 Aug; 17(12):1693-701. PubMed ID: 27359268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
